Molecular farming - The slope of enlightenment

被引:107
作者
Fischer, Rainer [1 ,2 ,3 ]
Buyel, Johannes F. [2 ,4 ]
机构
[1] IBRI, 1345 W 16th St,Suite 300, Indianapolis, IN 45202 USA
[2] Rhein Westfal TH Aachen, Inst Mol Biotechnol, Worringerweg 1, D-52074 Aachen, Germany
[3] Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis, 207 S Martin Jischke Dr, W Lafayette, IN 47907 USA
[4] Fraunhofer Inst Mol Biol & Appl Ecol IME, Forckenbeckstr 6, D-52074 Aachen, Germany
关键词
Molecular farming; Plant platforms; Industrial and pharmaceutical products; Development cycle; Regulatory; LARGE-SCALE PRODUCTION; RECOMBINANT PHARMACEUTICAL PROTEINS; MONOCLONAL-ANTIBODY; COMMERCIAL PRODUCTION; HIGH-LEVEL; TOBACCO; PLANTS; EXPRESSION; CELL; VACCINES;
D O I
10.1016/j.biotechadv.2020.107519
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Molecular farming can be defined as the use of plants to produce recombinant protein products. The technology is now > 30 years old. The early promise of molecular farming was based on three perceived advantages: the low costs of growing plants, the immense scalability of agricultural production, and the inherent safety of plants as hosts for the production of pharmaceuticals. This resulted in a glut of research publications in which diverse proteins were expressed in equally diverse plant-based systems, and numerous companies were founded hoping to commercialize the new technology. There was a moderate degree of success for companies producing nonpharmaceutical proteins, but in the pharmaceutical sector the anticipation raised by promising early research was soon met by the cold hard reality of industrial pragmatism. Plants did not have a track record of success in pharmaceutical protein manufacturing, lacked a regulatory framework, and did not perform as well as established industry platforms. Negative attitudes towards genetically modified plants added to the mix. By the early 2000s, major industry players started to lose interest and pharmaceutical molecular farming fell from a peak of expectation into a trough of disillusionment, just as predicted by the Gartner hype cycle. But many of the pioneers of molecular farming have refocused their activities and have worked to address the limitations that hampered the first generation of technologies. The field has now consolidated around a smaller number of better-characterized platforms and has started to develop standardized methods and best practices, mirroring the evolution of more mature industry sectors. Likewise, attention has turned from proof-of-principle studies to realistic techno-economic modeling to capture significant niche markets, replicating the success of the industrial molecular farming sector. Here we argue that these recent developments signify that pharmaceutical molecular farming is now climbing the slope of enlightenment and will soon emerge as a mature technology.
引用
收藏
页数:16
相关论文
共 112 条
[1]   A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme-A Preclinical and Phase I Investigation [J].
Aviezer, David ;
Brill-Almon, Einat ;
Shaaltiel, Yoseph ;
Hashmueli, Sharon ;
Bartfeld, Daniel ;
Mizrachi, Sarah ;
Liberman, Yael ;
Freeman, Arnold ;
Zimran, Ari ;
Galun, Eithan .
PLOS ONE, 2009, 4 (03)
[2]   Novel enzyme replacement therapy for Gaucher disease: Ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells [J].
Aviezer, David ;
Almon-Brill, Einat ;
Shaaltiel, Yoseph ;
Galili, Gad ;
Chertkoff, Raul ;
Hashmueli, Sharon ;
Galun, Eithan ;
Zimran, Ari .
MOLECULAR GENETICS AND METABOLISM, 2009, 96 (02) :S13-S14
[3]   Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma [J].
Bendandi, M. ;
Marillonnet, S. ;
Kandzia, R. ;
Thieme, F. ;
Nickstadt, A. ;
Herz, S. ;
Froede, R. ;
Inoges, S. ;
Lopez-Diaz de Cerio, A. ;
Soria, E. ;
Villanueva, H. ;
Vancanneyt, G. ;
McCormick, A. ;
Tuse, D. ;
Lenz, J. ;
Butler-Ransohoff, J. -E. ;
Klimyuk, V. ;
Gleba, Y. .
ANNALS OF ONCOLOGY, 2010, 21 (12) :2420-2427
[4]   Design of a Type-1 Diabetes Vaccine Candidate Using Edible Plants Expressing a Major Autoantigen [J].
Bertini, Edoardo ;
Merlin, Matilde ;
Gecchele, Elisa ;
Puggia, Andrea ;
Brozzetti, Annalisa ;
Commisso, Mauro ;
Falorni, Alberto ;
Bini, Vittorio ;
Klymyuk, Victor ;
Pezzotti, Mario ;
Avesani, Linda .
FRONTIERS IN PLANT SCIENCE, 2018, 9
[5]   Engineering Plastid Genomes: Methods, Tools, and Applications in Basic Research and Biotechnology [J].
Bock, Ralph .
ANNUAL REVIEW OF PLANT BIOLOGY, VOL 66, 2015, 66 :211-241
[6]   Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate-Tackling the Cocktail Challenge [J].
Boes, Alexander ;
Spiegel, Holger ;
Voepel, Nadja ;
Edgue, Gueven ;
Beiss, Veronique ;
Kapelski, Stephanie ;
Fendel, Rolf ;
Scheuermayer, Matthias ;
Pradel, Gabriele ;
Bolscher, Judith M. ;
Behet, Marije C. ;
Dechering, Koen J. ;
Hermsen, Cornelus C. ;
Sauerwein, Robert W. ;
Schillberg, Stefan ;
Reimann, Andreas ;
Fischer, Rainer .
PLOS ONE, 2015, 10 (07)
[7]   Production of recombinant proteins in plant root exudates [J].
Borisjuk, NV ;
Borisjuk, LG ;
Logendra, S ;
Petersen, F ;
Gleba, Y ;
Raskin, I .
NATURE BIOTECHNOLOGY, 1999, 17 (05) :466-469
[8]   BACTERIAL DRY-MATTER CONTENT AND BIOMASS ESTIMATIONS [J].
BRATBAK, G ;
DUNDAS, I .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1984, 48 (04) :755-757
[9]   Tobacco BY-2 cell-free lysate: an alternative and highly-productive plant-based in vitro translation system [J].
Buntru, Matthias ;
Vogel, Simon ;
Spiegel, Holger ;
Schillberg, Stefan .
BMC BIOTECHNOLOGY, 2014, 14
[10]   Very-large-scale production of antibodies in plants: The biologization of manufacturing [J].
Buyel, J. F. ;
Twyman, R. M. ;
Fischer, R. .
BIOTECHNOLOGY ADVANCES, 2017, 35 (04) :458-465